Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream aims to soothe rash caused by cancer drugs

NCT ID NCT04731259

Symptom relief Sponsor: Azitra Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a cream called ATR-04 to see if it could safely reduce the facial rash caused by certain cancer drugs (EGFR inhibitors). About 60 adults with cancer who were about to start these drugs were planned to join. The study was withdrawn before any participants enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Expected to start

Jan 2024

An estimate. Start dates often move.

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be at least 18 years of age inclusive, at the time of signing the informed consent * Subjects with a current diagnosis of cancer * IGA grade of 0 on the face * Life expectancy, in the Investigator's opinion, greater than 12 weeks * Plan to initiate treatment with one of the following EGFRI drugs (other treatments may be considered after consultation with the Sponsor): Cetuximab or Panitumumab or erlotinib * Able to use Dove sensitive skin body wash for the duration of the treatment period. * Acceptable and willing to delay start of EGFRI therapy until study eligibility is determined * Anticipated to continue EGFRI therapy for at least 28 days after the first application of study medication * Male and/or female * Contraceptive use by men or women consistent with the EGFRI treatment package insert regarding the methods of contraception for those participating in clinical studies * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol. Exclusion Criteria: * Active bacterial skin infections on the face * Inter-current illness that in the Investigator's opinion puts the subject at undue risk by study participation or interfere with the study conduct or evaluations * Pregnant women * EGFRI therapy within the previous 12 weeks * Radiation therapy exposure to the face within the previous 8 weeks * Use of topical steroids on the face within the previous 4 weeks * Use of systemic antibiotics or topical antibiotics on the face in the previous 7 days * Participation in an investigational clinical study in which administration of an investigational study medication occurred with the previous 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer rosacea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epidermal growth factor Papulopustular rosacea

More trials for these conditions

Other studies related to the condition(s) this trial covers.